Labcorp (NYSE: LH), a leading global life sciences company, today announced that it has closed its acquisition of RWJBarnabas Health’s outreach laboratory business and select related assets. RWJBarnabas Health is New Jersey’s largest academic health system.
“The communities, physicians and health systems we serve are central to everything we do at Labcorp,” said Bill Haas, senior vice president of Labcorp Diagnostic’s Northeast Division. “Our expanded relationship with RWJBH will build on the solid foundation RWJBarnabas Health has developed, and will offer patients and providers enhanced access to high-quality laboratory services, seamless data integration and connectivity and exceptional value to help improve patient care and outcomes.”
Through this collaboration, RWJBarnabas Health’s physicians and patients will be able to access an expanded test menu, as well as Labcorp’s extensive network of patient service centers, which includes Labcorp at Walgreens. In addition, for patients who have been served by a RWJBarnabas Health laboratory, Labcorp will offer expanded health plan coverage, enhanced service to rural markets and the potential for reduced out-of-pocket lab costs for patients. Same day and STAT testing will also be available in local communities.
“At RWJBarnabas Health, we take pride in creating and sustaining healthy communities by providing high-quality health care throughout New Jersey,” said John Doll, senior executive vice president and chief operations officer of RWJBarnabas Health. “By working alongside Labcorp, we will provide comprehensive testing services and enhance the laboratory service offerings. We are always evaluating how best to serve our patients, clinicians and physicians. This strategic business decision will provide a high-performing, streamlined outreach network to support our community.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Additional terms of the transaction were not disclosed.
Forward-Looking Statement
This press release contains forward-looking statements, including but not limited to statements with respect to the acquisition of the outreach laboratory business of RWJBarnabas Health and its anticipated benefits for providers and patients.
Each of the forward-looking statements is subject to change based on various important factors, many of which are beyond the company’s control. These factors, in some cases, have affected and in the future (together with other factors) could affect the company’s ability to implement the company’s business strategy and actual results could differ materially from those suggested by these forward-looking statements. As a result, readers are cautioned not to place undue reliance on any of the forward-looking statements.
The company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Further information on potential factors, risks and uncertainties that could affect operating and financial results is included in the company’s most recent Annual Report on Form 10-K and subsequent Forms 10-Q, including in each case under the heading RISK FACTORS, and in the company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the company’s filings with the SEC including the information in the company’s most recent Annual Report on Form 10-K, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Source: Biospace
